Blood Analyzers in Washington

Solomon Park Research Laboratories has supplied high-quality human serum, plasma, and biospecimens to clinical and research laboratories globally since 1984. Operating from their Burien, Washington facility, they specialize in commutable quality blood products collected via the CDC-developed CLSI C37-A procedure. Their offerings include AccuBase-CQM™ frozen serum and plasma with known analyte levels (lipids, chemistry markers), fresh whole blood and urine pools, and SPRL-RefKits™ analyte reference control kits for CAP proficiency testing and equipment calibration. Solomon Park also provides cryogenic ultra-low temperature storage (SPRL-StoTrac™) with 24/7 redundant power protection for longitudinal studies and global logistics. They support over 2,000 customers across 10 countries, offering custom donor acquisition, characterization, and proficiency testing materials for equipment manufacturers, metrology experts, and diagnostic equipment validation.

Magnolia Medical Technologies develops diagnostic solutions focused on reducing blood culture contamination and improving sepsis diagnostic accuracy. The company's flagship product is the Steripath® Micro Initial Specimen Diversion Device®, an FDA 510(k)-cleared device designed to reduce false-positive blood culture results in sepsis testing. The Steripath Platform is offered in two configurations: Steripath Micro for Direct to Media and Steripath Micro for Syringe Draws, supporting both peripheral venipuncture and peripheral IV start collection methods. Clinical studies demonstrate 83–88% contamination rate reduction depending on collection method. The device addresses a critical clinical challenge: blood culture contamination and misdiagnosis lead to unnecessary broad-spectrum antibiotic use, driving antibiotic resistance, Clostridioides difficile infections, and an estimated $6 billion in annual U.S. healthcare waste. Magnolia's platform is trusted by major hospital systems and health networks including Ascension, Premier, Cardinal Health, VA, Vizient, and HealthTrust, with clinical validation published in peer-reviewed journals including Clinical Infectious Diseases, Journal of Hospital Infection, and American Journal of Medical Quality. The company emphasizes diagnostic stewardship and quality outcomes improvement, with recognition from Newsweek for infection prevention innovation.

InBios International, Inc. is a privately-held biotechnology company specializing in the design, development, and manufacture of immunodiagnostic devices for infectious diseases and biothreats. Founded in 1996 and headquartered in Seattle, Washington, the company operates a state-of-the-art GMP-compliant, FDA-registered manufacturing facility certified to ISO 13485:2016. InBios maintains a portfolio of over 25 FDA-cleared diagnostic products and extensive life science reagent catalogs. Core offerings include ELISA kits, rapid point-of-care tests, and contract manufacturing services for emerging infectious disease diagnostics. The company delivers immunoassays targeting dengue, West Nile virus, Zika, Chagas disease, leishmaniasis, COVID-19, influenza, and biothreats such as anthrax and melioidosis. InBios provides comprehensive assay development, regulatory affairs support, and contract manufacturing capabilities to clinical laboratories, public health agencies, research institutions, and OEM partners globally. The company is recognized for rapid response to emerging disease threats while maintaining rigorous quality standards and cost-effective solutions for the global diagnostic market.